nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—hypertension—focal segmental glomerulosclerosis	0.483	1	CtDrD
Irbesartan—AGTR1—focal segmental glomerulosclerosis	0.346	1	CbGaD
Irbesartan—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0259	0.365	CbGbCtD
Irbesartan—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.018	0.255	CbGbCtD
Irbesartan—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0165	0.233	CbGbCtD
Irbesartan—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0105	0.148	CbGbCtD
Irbesartan—JUN—nephron—focal segmental glomerulosclerosis	0.0066	0.237	CbGeAlD
Irbesartan—AGTR1—nephron—focal segmental glomerulosclerosis	0.00497	0.179	CbGeAlD
Irbesartan—JUN—endothelium—focal segmental glomerulosclerosis	0.00311	0.112	CbGeAlD
Irbesartan—AGTR1—endothelium—focal segmental glomerulosclerosis	0.00234	0.0842	CbGeAlD
Irbesartan—Tasosartan—AGTR2—focal segmental glomerulosclerosis	0.00153	0.325	CrCbGaD
Irbesartan—JUN—nephron tubule—focal segmental glomerulosclerosis	0.00142	0.0512	CbGeAlD
Irbesartan—EDNRA—cortex of kidney—focal segmental glomerulosclerosis	0.00134	0.048	CbGeAlD
Irbesartan—JUN—kidney—focal segmental glomerulosclerosis	0.00125	0.045	CbGeAlD
Irbesartan—JUN—cortex of kidney—focal segmental glomerulosclerosis	0.00122	0.0438	CbGeAlD
Irbesartan—Stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.0394	CcSEcCtD
Irbesartan—AGTR1—nephron tubule—focal segmental glomerulosclerosis	0.00107	0.0385	CbGeAlD
Irbesartan—PTGS1—endothelium—focal segmental glomerulosclerosis	0.00103	0.037	CbGeAlD
Irbesartan—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.000953	0.0314	CcSEcCtD
Irbesartan—Trauma—Cyclosporine—focal segmental glomerulosclerosis	0.000953	0.0314	CcSEcCtD
Irbesartan—AGTR1—kidney—focal segmental glomerulosclerosis	0.000943	0.0339	CbGeAlD
Irbesartan—Bursitis—Cyclosporine—focal segmental glomerulosclerosis	0.000939	0.031	CcSEcCtD
Irbesartan—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.000926	0.0305	CcSEcCtD
Irbesartan—AGTR1—cortex of kidney—focal segmental glomerulosclerosis	0.000918	0.033	CbGeAlD
Irbesartan—Forasartan—AGTR1—focal segmental glomerulosclerosis	0.000877	0.186	CrCbGaD
Irbesartan—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.000578	0.0191	CcSEcCtD
Irbesartan—Tasosartan—AGTR1—focal segmental glomerulosclerosis	0.000532	0.113	CrCbGaD
Irbesartan—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.000513	0.0169	CcSEcCtD
Irbesartan—CYP2C8—kidney—focal segmental glomerulosclerosis	0.000511	0.0184	CbGeAlD
Irbesartan—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.000506	0.0167	CcSEcCtD
Irbesartan—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000489	0.0161	CcSEcCtD
Irbesartan—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.000486	0.016	CcSEcCtD
Irbesartan—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.000462	0.0152	CcSEcCtD
Irbesartan—Valsartan—AGTR1—focal segmental glomerulosclerosis	0.000461	0.0977	CrCbGaD
Irbesartan—Olmesartan—AGTR1—focal segmental glomerulosclerosis	0.000449	0.0952	CrCbGaD
Irbesartan—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000446	0.0147	CcSEcCtD
Irbesartan—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.000429	0.0141	CcSEcCtD
Irbesartan—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.000415	0.0137	CcSEcCtD
Irbesartan—PTGS1—kidney—focal segmental glomerulosclerosis	0.000415	0.0149	CbGeAlD
Irbesartan—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000379	0.0125	CcSEcCtD
Irbesartan—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000377	0.0124	CcSEcCtD
Irbesartan—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000372	0.0123	CcSEcCtD
Irbesartan—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.000359	0.0118	CcSEcCtD
Irbesartan—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.000352	0.0116	CcSEcCtD
Irbesartan—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000351	0.0116	CcSEcCtD
Irbesartan—Candesartan—AGTR1—focal segmental glomerulosclerosis	0.000349	0.074	CrCbGaD
Irbesartan—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.000349	0.0115	CcSEcCtD
Irbesartan—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.000348	0.0115	CcSEcCtD
Irbesartan—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000346	0.0124	CbGeAlD
Irbesartan—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.0114	CcSEcCtD
Irbesartan—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000341	0.0122	CbGeAlD
Irbesartan—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000339	0.0112	CcSEcCtD
Irbesartan—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.000324	0.0107	CcSEcCtD
Irbesartan—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000312	0.0103	CcSEcCtD
Irbesartan—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000301	0.00992	CcSEcCtD
Irbesartan—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000298	0.00982	CcSEcCtD
Irbesartan—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.000297	0.00978	CcSEcCtD
Irbesartan—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000291	0.00958	CcSEcCtD
Irbesartan—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000287	0.00945	CcSEcCtD
Irbesartan—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000285	0.00939	CcSEcCtD
Irbesartan—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000279	0.00921	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000265	0.00873	CcSEcCtD
Irbesartan—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000259	0.00855	CcSEcCtD
Irbesartan—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000257	0.00847	CcSEcCtD
Irbesartan—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00842	CcSEcCtD
Irbesartan—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00025	0.00825	CcSEcCtD
Irbesartan—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00025	0.00823	CcSEcCtD
Irbesartan—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000249	0.00821	CcSEcCtD
Irbesartan—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000248	0.00816	CcSEcCtD
Irbesartan—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000247	0.00814	CcSEcCtD
Irbesartan—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000247	0.00814	CcSEcCtD
Irbesartan—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.00792	CcSEcCtD
Irbesartan—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.0079	CcSEcCtD
Irbesartan—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000229	0.00754	CcSEcCtD
Irbesartan—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000228	0.00752	CcSEcCtD
Irbesartan—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000227	0.00748	CcSEcCtD
Irbesartan—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000226	0.00746	CcSEcCtD
Irbesartan—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000225	0.00742	CcSEcCtD
Irbesartan—Losartan—AGTR1—focal segmental glomerulosclerosis	0.000225	0.0477	CrCbGaD
Irbesartan—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00739	CcSEcCtD
Irbesartan—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000223	0.00737	CcSEcCtD
Irbesartan—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00022	0.00724	CcSEcCtD
Irbesartan—JUN—BCR signaling pathway—CD79A—focal segmental glomerulosclerosis	0.000213	0.00571	CbGpPWpGaD
Irbesartan—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000213	0.00701	CcSEcCtD
Irbesartan—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000212	0.00698	CcSEcCtD
Irbesartan—JUN—Osteopontin-mediated events—MMP2—focal segmental glomerulosclerosis	0.000211	0.00568	CbGpPWpGaD
Irbesartan—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000207	0.00682	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—COL4A4—focal segmental glomerulosclerosis	0.000206	0.00553	CbGpPWpGaD
Irbesartan—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000205	0.00677	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000205	0.00551	CbGpPWpGaD
Irbesartan—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000205	0.00674	CcSEcCtD
Irbesartan—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000204	0.00671	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000204	0.00546	CbGpPWpGaD
Irbesartan—EDNRA—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.000203	0.00546	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.000199	0.00536	CbGpPWpGaD
Irbesartan—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000198	0.00654	CcSEcCtD
Irbesartan—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000196	0.00645	CcSEcCtD
Irbesartan—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000195	0.00642	CcSEcCtD
Irbesartan—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.00641	CcSEcCtD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.000193	0.00518	CbGpPWpGaD
Irbesartan—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000193	0.00636	CcSEcCtD
Irbesartan—JUN—TGF-beta Receptor Signaling—SPP1—focal segmental glomerulosclerosis	0.000192	0.00515	CbGpPWpGaD
Irbesartan—JUN—FGF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000192	0.00515	CbGpPWpGaD
Irbesartan—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000191	0.00629	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—COL4A1—focal segmental glomerulosclerosis	0.000189	0.00508	CbGpPWpGaD
Irbesartan—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000187	0.00617	CcSEcCtD
Irbesartan—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000186	0.00613	CcSEcCtD
Irbesartan—JUN—Endothelins—EDN1—focal segmental glomerulosclerosis	0.000184	0.00495	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000184	0.00607	CcSEcCtD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—focal segmental glomerulosclerosis	0.000184	0.00493	CbGpPWpGaD
Irbesartan—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000183	0.00605	CcSEcCtD
Irbesartan—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000182	0.00601	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000182	0.00488	CbGpPWpGaD
Irbesartan—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000181	0.00598	CcSEcCtD
Irbesartan—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000179	0.0059	CcSEcCtD
Irbesartan—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000178	0.00588	CcSEcCtD
Irbesartan—JUN—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000178	0.00477	CbGpPWpGaD
Irbesartan—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000178	0.00586	CcSEcCtD
Irbesartan—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000173	0.00571	CcSEcCtD
Irbesartan—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000171	0.00565	CcSEcCtD
Irbesartan—EDNRA—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00017	0.00456	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000169	0.00455	CbGpPWpGaD
Irbesartan—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00557	CcSEcCtD
Irbesartan—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00557	CcSEcCtD
Irbesartan—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00557	CcSEcCtD
Irbesartan—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00555	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00553	CcSEcCtD
Irbesartan—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000167	0.0055	CcSEcCtD
Irbesartan—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000165	0.00545	CcSEcCtD
Irbesartan—JUN—Validated nuclear estrogen receptor alpha network—PCNA—focal segmental glomerulosclerosis	0.000164	0.00441	CbGpPWpGaD
Irbesartan—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000162	0.00534	CcSEcCtD
Irbesartan—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000162	0.00534	CcSEcCtD
Irbesartan—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000161	0.00531	CcSEcCtD
Irbesartan—AGTR1—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.000159	0.00428	CbGpPWpGaD
Irbesartan—JUN—Osteopontin-mediated events—MMP9—focal segmental glomerulosclerosis	0.000159	0.00427	CbGpPWpGaD
Irbesartan—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000159	0.00524	CcSEcCtD
Irbesartan—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000159	0.00523	CcSEcCtD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000158	0.00425	CbGpPWpGaD
Irbesartan—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00519	CcSEcCtD
Irbesartan—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00516	CcSEcCtD
Irbesartan—AGTR1—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.000157	0.0042	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000156	0.00419	CbGpPWpGaD
Irbesartan—EDNRA—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.000155	0.00417	CbGpPWpGaD
Irbesartan—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00509	CcSEcCtD
Irbesartan—EDNRA—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.000153	0.00412	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000152	0.00408	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000148	0.00487	CcSEcCtD
Irbesartan—JUN—ATF-2 transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000147	0.00395	CbGpPWpGaD
Irbesartan—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000145	0.0048	CcSEcCtD
Irbesartan—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000144	0.00476	CcSEcCtD
Irbesartan—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000144	0.00475	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000143	0.00383	CbGpPWpGaD
Irbesartan—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000143	0.0047	CcSEcCtD
Irbesartan—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000141	0.00464	CcSEcCtD
Irbesartan—JUN—AP-1 transcription factor network—AGT—focal segmental glomerulosclerosis	0.000141	0.00378	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.00461	CcSEcCtD
Irbesartan—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.0046	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.000139	0.00373	CbGpPWpGaD
Irbesartan—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000138	0.00457	CcSEcCtD
Irbesartan—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000138	0.00457	CcSEcCtD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—focal segmental glomerulosclerosis	0.000138	0.0037	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000135	0.00364	CbGpPWpGaD
Irbesartan—JUN—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000135	0.00361	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—NOS2—focal segmental glomerulosclerosis	0.000135	0.00361	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—TGFB1—focal segmental glomerulosclerosis	0.000134	0.00361	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000134	0.00359	CbGpPWpGaD
Irbesartan—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000133	0.0044	CcSEcCtD
Irbesartan—AGTR1—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.000133	0.00358	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—SERPINE1—focal segmental glomerulosclerosis	0.000133	0.00357	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000132	0.00437	CcSEcCtD
Irbesartan—EDNRA—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000132	0.00354	CbGpPWpGaD
Irbesartan—Losartan—ACE—focal segmental glomerulosclerosis	0.00013	0.0276	CrCbGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00013	0.00349	CbGpPWpGaD
Irbesartan—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000129	0.00424	CcSEcCtD
Irbesartan—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.00422	CcSEcCtD
Irbesartan—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.00422	CcSEcCtD
Irbesartan—CYP2D6—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000127	0.00341	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—MMP2—focal segmental glomerulosclerosis	0.000126	0.00339	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	0.000125	0.00335	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000123	0.00329	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00012	0.00322	CbGpPWpGaD
Irbesartan—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000119	0.00393	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000119	0.0032	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—MMP2—focal segmental glomerulosclerosis	0.000118	0.00318	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000118	0.00318	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000118	0.00316	CbGpPWpGaD
Irbesartan—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00383	CcSEcCtD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—GNAQ—focal segmental glomerulosclerosis	0.000116	0.00311	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	0.000116	0.0031	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—SPP1—focal segmental glomerulosclerosis	0.000115	0.00309	CbGpPWpGaD
Irbesartan—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000115	0.00378	CcSEcCtD
Irbesartan—JUN—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000113	0.00304	CbGpPWpGaD
Irbesartan—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000111	0.00365	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.000111	0.00297	CbGpPWpGaD
Irbesartan—EDNRA—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000109	0.00294	CbGpPWpGaD
Irbesartan—Valsartan—ALB—focal segmental glomerulosclerosis	0.000109	0.0231	CrCbGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.000108	0.0029	CbGpPWpGaD
Irbesartan—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000108	0.00289	CbGpPWpGaD
Irbesartan—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000107	0.00353	CcSEcCtD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000105	0.00282	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000103	0.00277	CbGpPWpGaD
Irbesartan—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000103	0.0034	CcSEcCtD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000103	0.00276	CbGpPWpGaD
Irbesartan—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000102	0.00337	CcSEcCtD
Irbesartan—AGTR1—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.000102	0.00274	CbGpPWpGaD
Irbesartan—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000102	0.00336	CcSEcCtD
Irbesartan—JUN—FGF signaling pathway—MMP9—focal segmental glomerulosclerosis	0.000102	0.00274	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000102	0.00274	CbGpPWpGaD
Irbesartan—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000101	0.00335	CcSEcCtD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—focal segmental glomerulosclerosis	9.91e-05	0.00266	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	9.78e-05	0.00263	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—SERPINE1—focal segmental glomerulosclerosis	9.62e-05	0.00258	CbGpPWpGaD
Irbesartan—Nausea—Cyclosporine—focal segmental glomerulosclerosis	9.62e-05	0.00317	CcSEcCtD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	9.55e-05	0.00257	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—GNAQ—focal segmental glomerulosclerosis	9.4e-05	0.00252	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	9.4e-05	0.00252	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	9.24e-05	0.00248	CbGpPWpGaD
Irbesartan—JUN—IL-3 Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	9.08e-05	0.00244	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—SPP1—focal segmental glomerulosclerosis	9e-05	0.00242	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—SPP1—focal segmental glomerulosclerosis	8.94e-05	0.0024	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—MMP9—focal segmental glomerulosclerosis	8.9e-05	0.00239	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—PCNA—focal segmental glomerulosclerosis	8.78e-05	0.00236	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	8.75e-05	0.00235	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	8.72e-05	0.00234	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	8.68e-05	0.00233	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	8.58e-05	0.0023	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	8.47e-05	0.00227	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TGFB1—focal segmental glomerulosclerosis	8.4e-05	0.00226	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	8.3e-05	0.00223	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—MMP9—focal segmental glomerulosclerosis	8.28e-05	0.00222	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	8e-05	0.00215	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	7.84e-05	0.0021	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—FN1—focal segmental glomerulosclerosis	7.83e-05	0.0021	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	7.82e-05	0.0021	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	7.81e-05	0.0021	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	7.67e-05	0.00206	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—focal segmental glomerulosclerosis	7.45e-05	0.002	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	7.24e-05	0.00194	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	7.21e-05	0.00194	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	7.01e-05	0.00188	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—TGFB1—focal segmental glomerulosclerosis	6.99e-05	0.00188	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	6.85e-05	0.00184	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	6.84e-05	0.00184	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TGFB1—focal segmental glomerulosclerosis	6.83e-05	0.00183	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	6.64e-05	0.00178	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—MMP2—focal segmental glomerulosclerosis	6.33e-05	0.0017	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	6.29e-05	0.00169	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	6.27e-05	0.00168	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MYH9—focal segmental glomerulosclerosis	6.27e-05	0.00168	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—SERPINE1—focal segmental glomerulosclerosis	6.21e-05	0.00167	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—FN1—focal segmental glomerulosclerosis	5.85e-05	0.00157	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	5.79e-05	0.00155	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	5.76e-05	0.00155	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	5.68e-05	0.00153	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	5.58e-05	0.0015	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	5.52e-05	0.00148	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	5.51e-05	0.00148	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	5.44e-05	0.00146	CbGpPWpGaD
Irbesartan—Losartan—ALB—focal segmental glomerulosclerosis	5.33e-05	0.0113	CrCbGaD
Irbesartan—EDNRA—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	5.26e-05	0.00141	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	5.23e-05	0.0014	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	5.21e-05	0.0014	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	5e-05	0.00134	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	4.94e-05	0.00133	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIAS1—focal segmental glomerulosclerosis	4.93e-05	0.00132	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	4.84e-05	0.0013	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TGFB1—focal segmental glomerulosclerosis	4.79e-05	0.00129	CbGpPWpGaD
Irbesartan—UGT1A3—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	4.7e-05	0.00126	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	4.65e-05	0.00125	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	4.54e-05	0.00122	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	4.52e-05	0.00121	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	4.43e-05	0.00119	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	4.4e-05	0.00118	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	4.33e-05	0.00116	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	4.27e-05	0.00115	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.22e-05	0.00113	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	4.13e-05	0.00111	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	4.11e-05	0.0011	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	4.1e-05	0.0011	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	4.02e-05	0.00108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.92e-05	0.00105	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	3.8e-05	0.00102	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	3.75e-05	0.00101	CbGpPWpGaD
Irbesartan—JUN—Immune System—MYH9—focal segmental glomerulosclerosis	3.65e-05	0.000981	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.52e-05	0.000945	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	3.45e-05	0.000926	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	3.41e-05	0.000915	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	3.39e-05	0.00091	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.32e-05	0.00089	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	3.19e-05	0.000856	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	3.12e-05	0.000837	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.11e-05	0.000834	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.1e-05	0.000832	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.09e-05	0.000829	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.06e-05	0.000821	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	3e-05	0.000804	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.95e-05	0.000791	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.93e-05	0.000787	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.83e-05	0.00076	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—LIPC—focal segmental glomerulosclerosis	2.78e-05	0.000747	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.67e-05	0.000718	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.6e-05	0.000697	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.48e-05	0.000665	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CTGF—focal segmental glomerulosclerosis	2.45e-05	0.000658	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.44e-05	0.000656	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.44e-05	0.000655	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.42e-05	0.000651	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.38e-05	0.000638	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.27e-05	0.00061	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.26e-05	0.000606	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.22e-05	0.000596	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD79A—focal segmental glomerulosclerosis	2.21e-05	0.000594	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.15e-05	0.000577	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.04e-05	0.000547	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.01e-05	0.000541	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2e-05	0.000537	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.95e-05	0.000525	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.85e-05	0.000497	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.85e-05	0.000497	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.84e-05	0.000493	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.82e-05	0.000489	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.81e-05	0.000486	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—focal segmental glomerulosclerosis	1.8e-05	0.000485	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—LPL—focal segmental glomerulosclerosis	1.7e-05	0.000456	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.67e-05	0.000449	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.63e-05	0.000437	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.58e-05	0.000424	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.58e-05	0.000424	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.57e-05	0.000421	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.54e-05	0.000415	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.53e-05	0.000412	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.52e-05	0.000409	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AGT—focal segmental glomerulosclerosis	1.45e-05	0.00039	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.45e-05	0.00039	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.41e-05	0.000378	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.39e-05	0.000374	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.39e-05	0.000374	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.39e-05	0.000372	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.38e-05	0.00037	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.31e-05	0.000352	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.29e-05	0.000345	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.27e-05	0.000341	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.21e-05	0.000325	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.19e-05	0.000319	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.18e-05	0.000317	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.15e-05	0.000308	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.13e-05	0.000303	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ALB—focal segmental glomerulosclerosis	1.11e-05	0.000299	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.08e-05	0.000291	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	1.01e-05	0.000272	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.01e-05	0.000271	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.84e-06	0.000264	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	9.8e-06	0.000263	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	9.66e-06	0.000259	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	9.65e-06	0.000259	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—LPL—focal segmental glomerulosclerosis	9.56e-06	0.000257	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	9.11e-06	0.000244	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	9.05e-06	0.000243	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	8.91e-06	0.000239	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	8.31e-06	0.000223	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	8.25e-06	0.000222	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	8.24e-06	0.000221	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.21e-06	0.00022	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AGT—focal segmental glomerulosclerosis	8.18e-06	0.00022	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.11e-06	0.000218	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.72e-06	0.000207	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.53e-06	0.000202	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7.41e-06	0.000199	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	7.32e-06	0.000196	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	7.25e-06	0.000195	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	7.04e-06	0.000189	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.74e-06	0.000181	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.68e-06	0.000179	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.37e-06	0.000171	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.33e-06	0.00017	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—focal segmental glomerulosclerosis	6.28e-06	0.000169	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	6.2e-06	0.000166	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	6.18e-06	0.000166	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.77e-06	0.000155	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.71e-06	0.000153	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	5.43e-06	0.000146	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	5.28e-06	0.000142	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	5.07e-06	0.000136	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	5.03e-06	0.000135	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	4.78e-06	0.000128	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.76e-06	0.000128	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.41e-06	0.000118	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	4.34e-06	0.000116	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	4.3e-06	0.000115	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	4.3e-06	0.000115	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	4.05e-06	0.000109	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	3.67e-06	9.87e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	3.33e-06	8.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	3.32e-06	8.9e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	3.3e-06	8.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.84e-06	7.62e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	2.82e-06	7.57e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.18e-06	5.84e-05	CbGpPWpGaD
